ストックスクリーナーアプリを入手
118.81
1.09%
1.28
プレマーケット:
118.91
0.10
+0.08%
Revolution Medicines Inc (RVMD) 最新ニュース
Jim Cramer Highlights "Takeover Interest" in Revolution Medicines - Finviz
Stifel Raises Price Target for RVMD to $170 with Buy Rating | RV - GuruFocus
Jim Cramer Highlights “Takeover Interest” in Revolution Medicines - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Teladoc (TDOC) and Immunome (IMNM) - The Globe and Mail
Merck Weighs Revolution Medicines Buyout And Expands AI Oncology Bet - simplywall.st
Guggenheim Raises Price Target for Revolution Medicines (RVMD) t - GuruFocus
Is Revolution Medicines Inc. Equity Warrant stock attractive for retirement portfolios2025 Year in Review & Daily Technical Stock Forecast Reports - bollywoodhelpline.com
Revolution Medicines gains breakthrough therapy status for zoldonrasib - MSN
Revolution Medicines gets FDA Breakthrough Therapy status for daraxonrasib - MSN
Revolution Medicines shares climb after FDA grants Orphan Drug Designation for pancreatic cancer treatment - MSN
Revolution Medicines Sees Unusually High Options Volume (NASDAQ:RVMD) - MarketBeat
Revolution Medicines stock hits all-time high at 121.62 USD By Investing.com - Investing.com Nigeria
Aug Wrap: Should I hold or sell INNEOVA Holdings Limited nowOptions Play & Verified Technical Trade Signals - baoquankhu1.vn
Revolution Medicines’ Stock Jumped On RAS Drug Hopes And Buyout Chatter - Finimize
Revolution Medicines (NASDAQ:RVMD) Sets New 1-Year HighStill a Buy? - MarketBeat
Revolution Medicines stock hits all-time high at 121.62 USD - Investing.com
Revolution Medicines (RVMD) Price Target Increased by 10.10% to 92.82 - Nasdaq
Merck reportedly in talks to buy Revolution in huge $28–32bn deal - BioXconomy
What sentiment indicators say about Revolution Medicines Inc. stockPortfolio Allocation Tips & We Spotted the Next Tesla – See Inside - bollywoodhelpline.com
Revolution Medicines (BIT:1RVMD) Price Target Increased by 13.08% to 76.84 - Nasdaq
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B - Stocktwits
Looking At Revolution Medicines's Recent Unusual Options Activity - Benzinga
J.P. Morgan: Revolution Awaits Key Readout As Merck Takeover Rumors Swirl - Citeline News & Insights
Mizuho Raises Price Target for RVMD to $143, Maintains Outperfor - GuruFocus
Merck (MRK) Acquisition Talks with Revolution Medicines: Analyst's Perspective - GuruFocus
Revolution Medicines declines to comment on M&A speculation at conference - MSN
Revolution Medicines (RVMD) Shares Dip Amid Merck Acquisition Ru - GuruFocus
Revolution Medicines: Dominant Pancreatic Cancer Position, Expanding RAS Franchise, and 2026 Catalyst Funnel Support Buy Rating - TipRanks
Revolution Medicines CEO Addresses Investor Questions on Merck Acquisition at J.P. Morgan Healthcare Conference - geneonline.com
Revolution Medicines stock gains as Stifel highlights strong PDAC position By Investing.com - Investing.com India
Revolution Medicines stock gains as Stifel highlights strong PDAC position - Investing.com
$30B ‘might not be enough’ for Revolution Medicines, says Stifel - TipRanks
With a grin — and tight lips — Revolution Medicines’ CEO faces questions about acquisition - statnews.com
RVMD Projects Significant Growth with Solid Financial Position b - GuruFocus
Revolution Medicines (RVMD) CEO Cancels Conference Appearance - GuruFocus
RVMD: Late-stage RAS-targeted therapies advance, with new resistance-overcoming drugs entering trials in 2026 - TradingView — Track All Markets
Revolution Medicines CEO says not commenting on ‘rumors or speculation’ - TipRanks
Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus - TechStock²
AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense - sharewise.com
Tema Etfs LLC Has $5.93 Million Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Pharmaceutical Giants Eye Revolution Medicines with $23 Billion Market Cap Amid Oncology M&A Surge - geneonline.com
Revolution Medicines: Take The Win And Sell Following Large Move Sparked By Buyout Rumors - Seeking Alpha
JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree - Pharmaceutical Technology
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Rating of "Buy" by Analysts - MarketBeat
Merck Could Strike 30 Billion Deal for Revolution Medicines - Oncodaily
Merck in Talks to Acquire Revolution Medicines for Approximately $30 Billion - Intellectia AI
RVMD stock hits a record high on rumored takeover interest - MSN
Sandisk, Bloom Energy, And Oklo Are Among the Top 10 Large-Cap Gainers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio? - Benzinga
AbbVie denies it’s in talks to buy Revolution Medicines. Both stocks are falling. - MSN
AbbVie in advanced talks to buy cancer drugmaker Revolution Medicines, shares jump nearly 30% - MSN
AbbVie says not in talks to buy Revolution Medicinesreport - MSN
Merck (MRK) Eyes $30 Billion Acquisition of Revolution Medicines - GuruFocus
AbbVie Inc. (ABBV) Gets Downgraded to Peer Perform From Outperform by Wolfe Research - Finviz
Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK - TechStock²
Erasca Stock Surges as Market Eyes Revolution Medicines Acquisition - StocksToTrade
0.37%
0.83%
大文字化:
|
ボリューム (24 時間):